Xuan Miao, Wang Bo, Bi Wanrong, Li Ying, Song Lige, Xie Zhuangli, Liu Qi, Zhang Xiuzhen
Department of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China.
Department of Endocrinology, School of Medicine, Yangpu Hospital, Tongji University, Shanghai, 200090, China.
Aging Clin Exp Res. 2025 Feb 22;37(1):44. doi: 10.1007/s40520-025-02932-w.
This study aimed to investigate the effect of electromagnetic field (EMF) combined with recombinant human parathyroid hormone (rhPTH) on bone mineral density (BMD) and bone turnover indicators in postmenopausal osteoporosis (PMOP) patients.
A total of 336 PMOP patients were randomly assigned into three groups: EMF + rhPTH group (n = 115), rhPTHx group (n = 113) and EMF group (n = 108). The lumbar spine and femoral neck BMDs were measured before treatment and at 6, 12, and 18 months after treatment. Blood calcium, bone alkaline phosphatase (BSAP), type I procollagen N-terminal peptide (PINP), and type I collagen C-terminal peptide/creatinine ratio (CTX/Cr) levels were measured before treatment and at 3, 6, 12, and 18 months after treatment.
The lumbar spine BMD was significantly increased at 6, 12, and 18 months after treatment, and the neck BMD was increased markedly at 18 months in both EMF + rhPTH group and rhPTH group as compared to those before treatment. There was significant difference in the lumbar spine BMD between EMF + rhPTH group and EMF group and between rhPTH group and EMF group at 6, 12, and 18 months after treatment. In the EMF + rhPTH group, at 3, 6, 12, and 18 months after treatment, blood calcium level was increased by 5.2%, 2.8%, 2.7%, and 3.1%, respectively; BASP level was increased by 80.9%, 120.3%, 84.1%, and 67.7%, respectively; PINP level was increased by 65.4%, 79.7%, 89.7%, and 74.5%, respectively; CTX/Cr was increased by 80.9%, 120.3%, 84.1%, and 67.7%, respectively; the bone metabolism indicators were markedly higher than those before treatment. In the rhPTH group, at 3, 6, 12, and 18 months after treatment, blood calcium level was increased by 5.1%, 3.3%, 3.0%, and 2.1%, respectively; BSAP level was increased by 51.6%, 81.4%, 101.1% and 56.3% respectively; PINP level was increased by 48.5%, 69.8%, 80.7% and 70.5% respectively; CTX/Cr was increased by 29.8%, 29.9%, 55.7%, and 44.8% respectively; the bone turnover indicators were significantly different from those before treatment (P < 0.01).
The combination of EMF and rhPTH can significantly improve the bone turnover and BMD of PMOP patients, and may serve as a clinical treatment of PMOP.
本研究旨在探讨电磁场（EMF）联合重组人甲状旁腺激素（rhPTH）对绝经后骨质疏松症（PMOP）患者骨密度（BMD）及骨转换指标的影响。
将336例PMOP患者随机分为三组：EMF+rhPTH组（n = 115）、rhPTH组（n = 113）和EMF组（n = 108）。于治疗前及治疗后6、12和18个月测量腰椎和股骨颈的骨密度。于治疗前及治疗后3、6、12和18个月测量血钙、骨碱性磷酸酶（BSAP）、I型前胶原N端肽（PINP）以及I型胶原C端肽/肌酐比值（CTX/Cr）水平。
与治疗前相比，EMF+rhPTH组和rhPTH组治疗后6、12和18个月时腰椎骨密度显著升高，18个月时股骨颈骨密度明显升高。治疗后6、12和18个月时，EMF+rhPTH组与EMF组之间以及rhPTH组与EMF组之间腰椎骨密度存在显著差异。在EMF+rhPTH组，治疗后3、6、12和18个月时，血钙水平分别升高5.2%、2.8%、2.7%和3.1%；BASP水平分别升高80.9%、120.3%、84.1%和67.7%；PINP水平分别升高65.4%、79.7%、89.7%和74.5%；CTX/Cr分别升高80.9%、120.3%、84.1%和67.7%；骨代谢指标明显高于治疗前。在rhPTH组，治疗后3、6、12和18个月时，血钙水平分别升高5.1%、3.3%、3.0%和2.1%；BSAP水平分别升高51.6%、81.4%、101.1%和56.3%；PINP水平分别升高48.5%、69.8%、80.7%和70.5%；CTX/Cr分别升高29.8%、29.9%、55.7%和44.8%；骨转换指标与治疗前有显著差异（P<0.01）。
EMF与rhPTH联合应用可显著改善PMOP患者的骨转换及骨密度，可能成为PMOP的一种临床治疗方法。
